[go: up one dir, main page]

ES2420079R1 - Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response. - Google Patents

Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response.

Info

Publication number
ES2420079R1
ES2420079R1 ES201230250A ES201230250A ES2420079R1 ES 2420079 R1 ES2420079 R1 ES 2420079R1 ES 201230250 A ES201230250 A ES 201230250A ES 201230250 A ES201230250 A ES 201230250A ES 2420079 R1 ES2420079 R1 ES 2420079R1
Authority
ES
Spain
Prior art keywords
immune response
small cell
cell lung
lung carcinoma
identification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201230250A
Other languages
Spanish (es)
Other versions
ES2420079B1 (en
ES2420079A2 (en
Inventor
Ortega Julian Sanz
Aldea Milagros Ferrer
Prieto Susana Hernandez
Lopez Alejandro Romera
Salgado Beatriz Perez-Villamil
Trancho Florentino Hernando
Martinez Ana Maria Gomez
Sarceda Jose Ramon Jarabo
Garcia Antonio Jose Torres
Garcia-Asenjo Jose Antonio Lopez
Larriba Jose Luis Gonzalez
Vazquez Javier Puente
Garcia Eduardo Diaz-Rubio
Garrido-Lestache Jose Luis Subiza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos
Original Assignee
Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos filed Critical Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos
Priority to ES201230250A priority Critical patent/ES2420079B1/en
Priority to PCT/ES2012/070919 priority patent/WO2013098457A1/en
Publication of ES2420079A2 publication Critical patent/ES2420079A2/en
Publication of ES2420079R1 publication Critical patent/ES2420079R1/en
Application granted granted Critical
Publication of ES2420079B1 publication Critical patent/ES2420079B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Método de clasificación del carcinoma no microcítico de pulmón basado en la identificación de una respuesta inmune intratumoral. La presente invención se refiere a un método in vitro de clasificación del carcinoma no microcítico de pulmón basado en la expresión diferencial de 50 genes. Dichos genes identifican una respuesta inmune intratumoral. Mediante el método de la invención se diferencian pacientes con un perfil de expresión de genes asociados a una respuesta inmune que se asocia con buen pronóstico y pacientes sin ese perfil de expresión que tienen peor pronóstico. Esa clasificación puede usarse como marcador pronóstico, como clasificador de los tumores en función de la respuesta inmune antitumoral ("inmunoscore") o como biomarcador predictor de terapias basadas en el sistema inmune (inmunoterapia). La presente invención también se refiere a un kit que comprende un conjunto de sondas que reconocen los 50 genes de la invención.Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response. The present invention relates to an in vitro method of classification of non-small cell lung carcinoma based on the differential expression of 50 genes. These genes identify an intratumoral immune response. By the method of the invention, patients with an expression profile of genes associated with an immune response that is associated with a good prognosis are distinguished and patients without that expression profile have a worse prognosis. This classification can be used as a prognostic marker, as a tumor classifier based on the antitumor immune response ("immunoscore") or as a biomarker predictor of immune system-based therapies (immunotherapy). The present invention also relates to a kit comprising a set of probes that recognize the 50 genes of the invention.

ES201230250A 2011-12-30 2012-02-17 Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response. Expired - Fee Related ES2420079B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201230250A ES2420079B1 (en) 2012-02-17 2012-02-17 Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response.
PCT/ES2012/070919 WO2013098457A1 (en) 2011-12-30 2012-12-28 Method for classifying non-microcytic lung carcinoma on the basis of identifying an intratumoral immune response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230250A ES2420079B1 (en) 2012-02-17 2012-02-17 Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response.

Publications (3)

Publication Number Publication Date
ES2420079A2 ES2420079A2 (en) 2013-08-21
ES2420079R1 true ES2420079R1 (en) 2013-09-11
ES2420079B1 ES2420079B1 (en) 2014-07-22

Family

ID=48906543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230250A Expired - Fee Related ES2420079B1 (en) 2011-12-30 2012-02-17 Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response.

Country Status (1)

Country Link
ES (1) ES2420079B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147205A1 (en) * 2007-06-01 2008-12-04 Agendia B.V. Prognostic gene expression signature for non small cell lung cancer patients
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
WO2010007093A1 (en) * 2008-07-17 2010-01-21 Universität Zu Köln A method for lung cancer early detection and prognosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
WO2008147205A1 (en) * 2007-06-01 2008-12-04 Agendia B.V. Prognostic gene expression signature for non small cell lung cancer patients
WO2010007093A1 (en) * 2008-07-17 2010-01-21 Universität Zu Köln A method for lung cancer early detection and prognosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
01/01/2009, ROEPMAN P et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.CLINICAL CANCER RESEARCH, 20090101 THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US 01/01/2009 VOL: 15 No: 1 Pags: 284 - 290 ISSN 1078-0432 Doi: doi:10.1158/1078-0432.CCR-08-1258; todo el documento, ,tabla 3. *

Also Published As

Publication number Publication date
ES2420079B1 (en) 2014-07-22
ES2420079A2 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
MX2021006791A (en) Methods and compositions for detecting misfolded proteins.
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
MX361058B (en) Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject.
JP2014144959A5 (en)
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
CA2951016C (en) PROSTATE CANCER DETECTION KIT OR DEVICE, AND ASSOCIATED DETECTION METHOD
WO2014143977A3 (en) Biomarkers and methods for predicting preeclampsia
MX340453B (en) Biomarkers for lung cancer.
WO2015082416A8 (en) Novel rna-biomarkers for diagnosis of prostate cancer
HK1246828A1 (en) Biomarker panel for the detection of cancer
UY36200A (en) SET OF SPECIFIC BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER
MA39776A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
PH12019550180A1 (en) A methylation classifier for detection of hpv-induced invasive cancers, nonhpv-induced gynaecological and anogenital cancers and their high-grade precursor lesions
EA201790549A1 (en) PREDICTIVE AND PROGNOSTIC BIOMARKERS ASSOCIATED WITH ANTIANGIOGENIC TREATMENT OF MALIGNANT TUMOR
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
BR112015019567A2 (en) markers associated with wnt inhibitors
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
ES2420079R1 (en) Classification method for non-small cell lung carcinoma based on the identification of an intratumoral immune response.
CR20210289A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
MX2014014829A (en) Autoimmune antibodies.
WO2015107430A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
WO2019013613A3 (en) Methods and kids for determining a risk of cancer
REN et al. Predictive effect of microRNA ratio in osteosarcoma
ZHANG et al. Clinical detecting application of TK1 in the diagnosis of common malignant tumors

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2420079

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140722

FD2A Announcement of lapse in spain

Effective date: 20211004